Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Viking Thera (VKTX)
Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,736,503
  • Shares Outstanding, K 100,029
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,870 K
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.53
Trade VKTX with:

Options Overview Details

View History
  • Implied Volatility 119.21% ( +18.19%)
  • Historical Volatility 88.63%
  • IV Percentile 75%
  • IV Rank 39.17%
  • IV High 230.04% on 10/03/23
  • IV Low 47.86% on 08/30/23
  • Put/Call Vol Ratio 0.09
  • Today's Volume 5,734
  • Volume Avg (30-Day) 4,527
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 80,415
  • Open Int (30-Day) 76,141

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.25
  • Number of Estimates 7
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.34 +84.58%
on 11/10/23
18.25 -5.53%
on 12/06/23
+6.83 (+65.61%)
since 11/06/23
3-Month
8.28 +108.21%
on 10/26/23
18.25 -5.53%
on 12/06/23
+2.61 (+17.84%)
since 09/06/23
52-Week
3.54 +387.01%
on 12/12/22
25.72 -32.97%
on 05/23/23
+13.52 (+363.44%)
since 12/06/22

Most Recent Stories

More News
1 Under-the-Radar Stock That Could Triple By 2030

This small-cap biotech stock is going to compete against some giants.

LLY : 589.25 (+0.19%)
VKTX : 17.24 (-0.69%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 2.57 (+8.90%)
RYTM : 37.23 (+1.14%)
VKTX : 17.24 (-0.69%)
GPCR : 60.73 (-1.25%)
NVO : 97.59 (-2.05%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 2.57 (+8.90%)
RYTM : 37.23 (+1.14%)
VKTX : 17.24 (-0.69%)
GPCR : 60.73 (-1.25%)
NVO : 97.59 (-2.05%)
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
Markets Today: Stocks Slip on Set-Back in Diplomatic Efforts to Contain Israel-Hamas Conflict

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.48%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.67%. Stock index futures this morning are moderately lower on this morning’s...

ESZ23 : 4,552.25 (-0.08%)
NQZ23 : 15,827.75 (+0.08%)
NVDA : 455.03 (-2.28%)
MS : 79.41 (-0.95%)
IBKR : 80.09 (+1.55%)
UAL : 40.93 (+3.38%)
AAL : 13.48 (+2.67%)
DAL : 38.94 (+3.54%)
ALK : 35.67 (+0.28%)
SHW : 286.71 (+1.31%)
CFG : 28.76 (-1.03%)
ALB : 118.30 (+4.45%)
S&P Futures Plunge as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap

December S&P 500 futures (ESZ23) are trending down -0.45% this morning as uncertainties lingered in the Middle East, and investors weighed the possibility of further rate hikes by the Federal Reserve while...

ESZ23 : 4,552.25 (-0.08%)
NVDA : 455.03 (-2.28%)
GS : 341.97 (+0.06%)
NTCT : 20.91 (+1.90%)
BAC : 30.53 (-0.16%)
DLTR : 126.03 (-1.35%)
TSLA : 239.37 (+0.27%)
NFLX : 446.73 (-1.85%)
PG : 146.65 (-0.07%)
ABT : 104.94 (+0.57%)
MS : 79.41 (-0.95%)
ADS.D.DX : 193.840 (-1.71%)
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
$VKTX: Consolidation in Viking Therapeutics Provides an Opportunity

Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid...

VKTX : 17.24 (-0.69%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 18.98
2nd Resistance Point 18.61
1st Resistance Point 17.93
Last Price 17.24
1st Support Level 16.88
2nd Support Level 16.51
3rd Support Level 15.83

See More

52-Week High 25.72
Fibonacci 61.8% 17.25
Last Price 17.24
Fibonacci 50% 14.63
Fibonacci 38.2% 12.01
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar